Log in to your Inderes Free account to see all free content on this page.

Orexo

25.00 SEK

+1.21 %

Less than 1K followers

ORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+1.21 %

-7.41 %

+7.07 %

+35.14 %

+42.86 %

+64.47 %

+36.31 %

-46.06 %

-72.21 %

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Market cap

928.92M SEK

Turnover

1.04M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

5.2.

2026

Annual report '25

28.4.

2026

Interim report Q1'26

7.5.

2026

General meeting '26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Press release12/1/2025, 11:00 AM

DNB Carnegie Access: Orexo - Ett händelserikt 2026 väntar

Press release10/24/2025, 6:17 AM

DNB Carnegie Access: Orexo: Deal delay behind share price drop – Q3 review

Press release10/23/2025, 7:15 AM

DNB Carnegie Access: Orexo: No major surprises – Q3 initial comment

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release10/23/2025, 6:00 AM

Orexo Q3 2025 Interim Report

Regulatory press release10/17/2025, 6:00 AM

Orexo´s Nomination Committee for the Annual General Meeting 2026

Press release10/16/2025, 12:03 PM

DNB Carnegie Access: Orexo: Pipeline focus – Q3 preview

Press release10/15/2025, 7:00 AM

Invitation to presentation of Orexo´s Q3 2025 Interim Report

Press release10/1/2025, 5:30 AM

Orexo strengthens innovation and research with move to new premises

Press release9/30/2025, 5:04 AM

DNB Carnegie Access: Orexo: Secures significant non-dilutive funding to advance OX390

Regulatory press release9/29/2025, 6:30 PM

Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership

Press release9/25/2025, 9:40 AM

BioStock: Video from Orexo's presentation at BioStock Investing in Life Science – From Seed to Success

Press release9/8/2025, 7:00 AM

Orexo to participate in Pareto Securities´ 16th Annual Healthcare Conference 2025

Press release9/5/2025, 8:12 AM

DNB Carnegie Access: Orexo: Promising preclinical data

Press release9/5/2025, 6:00 AM

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Press release9/2/2025, 1:17 PM

DNB Carnegie Access: Orexo: Highlights from DNB Carnegie’s Micro & Small Cap Day

Press release7/17/2025, 8:26 AM

DNB Carnegie Access: Orexo: Ongoing struggles, but not without positive signs – Q2 review

Orexo, Audiocast, Q2'25

Webcast7/16/2025, 12:00 PM

Orexo, Audiocast, Q2'25

Press release7/16/2025, 7:40 AM

DNB Carnegie Access: Orexo: Below our expectations – Q2 initial comment

Regulatory press release7/16/2025, 6:00 AM

Orexo Q2 2025 Interim Report

Press release7/7/2025, 11:00 AM

DNB Carnegie Access: Orexo: Set for decent quarter despite challenges – Q2 preview

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.